Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
VY1706 Alzheimer's Gene Therapy Achieves 75% Tau Reduction in GLP Studies
oyager Therapeutics reports preclinical data showing its VY1706 gene therapy reduces tau protein by 75% in Alzheimer's-relevant brain regions over 6 months.
FDA Grants RMAT Designation to Lexeo Therapeutics for LX2020 Gene Therapy
Lexeo Therapeutics receives FDA RMAT designation for LX2020, an investigational AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
AMT-191 Gene Therapy Shows Major Clinical Benefits in Fabry Disease Trial
uniQure’s investigational gene therapy AMT-191 boosted alpha-Gal A enzyme levels, allowing all dosed Fabry disease patients to stop replacement therapy.
FDA Grants Fast Track Designation to Modzatinib for Lichen Planus Treatment
Aclaris Therapeutics receives FDA Fast Track Designation for modzatinib (ATI-2138) to treat moderate to severe lichen planus. Phase 2b trial expected soon.
UC Davis Clinical Trial Reveals Best Air Purifiers for Asthma & Allergies
UC Davis and CARB conducted the largest clinical trial to find the best air purifiers for asthma and allergy control, highlighting HyperHEPA technology.
Generic Drug Tariffs: Trump Announces 0% Rate for 2 Years, Then Up to 200%
President Donald Trump announced generic drug imports will face a 0% tariff for 2 years, followed by 100% and 200% tariffs to encourage domestic production.
Preclinical and Clinical Services: GCCL and GemPharmatech Sign Global MOU
GCCL and GemPharmatech sign an MOU to integrate preclinical and clinical trial services across South Korea, the United States, and China markets.
Avanos Medical Stockholders Approve Acquisition by AIP for $25 Per Share
Avanos Medical stockholders vote to approve acquisition by American Industrial Partners at $25 per share in cash, with closing expected by July 27, 2026.
Tuberculosis Testing: CoSara Starts India Clinical Trial for PCR Platform
Co-Diagnostics joint venture CoSara Diagnostics initiates clinical studies in India for its rapid point-of-care tuberculosis test on the CoSara PCR Pro.
Cirrhosis Causes Shift: MASLD Becomes Leading Cause of US Liver Disease
A decade-long Veterans Health Administration study shows a shift in cirrhosis causes, with MASLD becoming the leading contributor to US liver disease cases.
Eli Lilly Acquires AtaiBeckley for $2.8B to Enter Psychedelic Medicine
Eli Lilly enters psychedelic drug development with a $2.8 billion acquisition of AtaiBeckley, gaining Phase 3 treatment-resistant depression therapies.
FDA Grants Full Approval to Novartis' Fabhalta for IgA Nephropathy Care
The FDA grants traditional approval to Novartis' Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN).
1
2
3
4
5
